Latest Synta Pharmaceuticals (SNTA) Headlines
Why Synta Pharmaceuticals Corp. Plunged Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Mar 12, 10:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals sank 16% today...
Stock to Watch: Synta Pharmaceuticals Down 16.5% (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 16.5% to $4.41 on 1.3x average daily volume. Thus far today, Synta Pharmaceuticals has traded 3.3 million shares, vs. average volume of 2.6 million shares per day. The stock has underperformed the Dow (-16.5% to the Dow's -0.2%) and underperformed the S&P 500 (-16.5% to the S&P's -0.2%) during today's trading.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Downgrade Alert for Synta Pharmaceuticals (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 7:04AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) was downgraded from Market Perform to Underperform at BMO Capital today. The stock closed yesterday at $5.28 on volume of 5.4 million shares, above average daily volume of 2.6 million. Over the past year, Synta Pharmaceuticals has traded in a range of $3.70 to $10.74 and closed yesterday at $5.28, 43% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has advanced 0.2%.
Why Synta Pharmaceuticals Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Today’s Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 11, 9:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Myriad Genetics...
Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Business Wire - Tue Mar 11, 6:04AM CDT
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on recent corporate events.
Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
Business Wire - Tue Mar 11, 6:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting (prior to surgery).
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Synta Pharmaceuticals Shares Up 18.4% Since SmarTrend's Buy Recommendation (SNTA)
Comtex SmarTrend(R) - Wed Mar 05, 9:11AM CST
SmarTrend identified an Uptrend for Synta Pharmaceuticals (NASDAQ:SNTA) on November 19th, 2013 at $5.16. In approximately 4 months, Synta Pharmaceuticals has returned 18.41% as of today's recent price of $6.11.
Synta Pharma CEO Sudden Resignation Might Trigger Overhaul
at The Street - Tue Mar 04, 8:33AM CST
Synta isn't saying why Safi Bahcall resigned as CEO but the stock has severely underperformed the market for the past year.
Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director
Business Wire - Mon Mar 03, 3:01PM CST
--Newly Formed Executive Committee to Act as Principle Executive Body Until Appointment of New Chief Executive Officer
Synta to Present on Hsp90-inhibitor Drug Conjugate Platform at the 12th International Congress on Targeted Anticancer Therapies
Business Wire - Fri Feb 28, 12:35PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the following late-breaking poster presentation will be made at the 12th International Congress on Targeted Anticancer Therapies in Washington, D.C.:
Synta to Present at Upcoming Conferences
Business Wire - Thu Feb 27, 3:05PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the following investor conferences:
Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2013 Financial Results on March 11, 2014
Business Wire - Wed Feb 26, 3:05PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its fourth quarter and year-end 2013 financial results on March 11, 2014, before market open.
Synta Pharmaceuticals Shares Up 34.1% Since SmarTrend's Buy Recommendation (SNTA)
Comtex SmarTrend(R) - Tue Feb 25, 4:43PM CST
SmarTrend identified an Uptrend for Synta Pharmaceuticals (NASDAQ:SNTA) on November 19th, 2013 at $5.16. In approximately 3 months, Synta Pharmaceuticals has returned 34.11% as of today's recent price of $6.92.
Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:25AM CST
Synta Pharmaceuticals was a big mover last session, with shares rising nearly 9%.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Why Synta Pharmaceuticals Corp. Plunged Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Mar 12, 10:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals sank 16% today...
Stock to Watch: Synta Pharmaceuticals Down 16.5% (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 16.5% to $4.41 on 1.3x average daily volume. Thus far today, Synta Pharmaceuticals has traded 3.3 million shares, vs. average volume of 2.6 million shares per day. The stock has underperformed the Dow (-16.5% to the Dow's -0.2%) and underperformed the S&P 500 (-16.5% to the S&P's -0.2%) during today's trading.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Downgrade Alert for Synta Pharmaceuticals (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 7:04AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) was downgraded from Market Perform to Underperform at BMO Capital today. The stock closed yesterday at $5.28 on volume of 5.4 million shares, above average daily volume of 2.6 million. Over the past year, Synta Pharmaceuticals has traded in a range of $3.70 to $10.74 and closed yesterday at $5.28, 43% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has advanced 0.2%.
Why Synta Pharmaceuticals Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Today’s Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 11, 9:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Myriad Genetics...
Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Business Wire - Tue Mar 11, 6:04AM CDT
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on recent corporate events.
Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
Business Wire - Tue Mar 11, 6:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting (prior to surgery).
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Synta Pharmaceuticals Shares Up 18.4% Since SmarTrend's Buy Recommendation (SNTA)
Comtex SmarTrend(R) - Wed Mar 05, 9:11AM CST
SmarTrend identified an Uptrend for Synta Pharmaceuticals (NASDAQ:SNTA) on November 19th, 2013 at $5.16. In approximately 4 months, Synta Pharmaceuticals has returned 18.41% as of today's recent price of $6.11.
Synta Pharma CEO Sudden Resignation Might Trigger Overhaul
at The Street - Tue Mar 04, 8:33AM CST
Synta isn't saying why Safi Bahcall resigned as CEO but the stock has severely underperformed the market for the past year.
Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director
Business Wire - Mon Mar 03, 3:01PM CST
--Newly Formed Executive Committee to Act as Principle Executive Body Until Appointment of New Chief Executive Officer
Synta to Present on Hsp90-inhibitor Drug Conjugate Platform at the 12th International Congress on Targeted Anticancer Therapies
Business Wire - Fri Feb 28, 12:35PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the following late-breaking poster presentation will be made at the 12th International Congress on Targeted Anticancer Therapies in Washington, D.C.:
Synta to Present at Upcoming Conferences
Business Wire - Thu Feb 27, 3:05PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the following investor conferences:
Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2013 Financial Results on March 11, 2014
Business Wire - Wed Feb 26, 3:05PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its fourth quarter and year-end 2013 financial results on March 11, 2014, before market open.
Synta Pharmaceuticals Shares Up 34.1% Since SmarTrend's Buy Recommendation (SNTA)
Comtex SmarTrend(R) - Tue Feb 25, 4:43PM CST
SmarTrend identified an Uptrend for Synta Pharmaceuticals (NASDAQ:SNTA) on November 19th, 2013 at $5.16. In approximately 3 months, Synta Pharmaceuticals has returned 34.11% as of today's recent price of $6.92.
Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:25AM CST
Synta Pharmaceuticals was a big mover last session, with shares rising nearly 9%.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
